Interference of bovine hemoglobin‐based oxygen carrier‐201 (Hemopure) on four hematology analyzers

Abstract

AbstractIntroductionHemoglobin‐based oxygen carriers, for example HBOC‐201 (Hemopure), are aimed to bridge acute anemia when blood transfusion is not available or refused by the patient. However, since HBOC‐201 appears free in plasma, it interferes with laboratory tests. This study presents an overview of HBOC‐201 interference on four commonly used hematology analyzers and suggests treatment monitoring possibilities.MethodsBlood samples were spiked with therapeutic doses of HBOC‐201 and nine hematology parameters were measured with the Sysmex XN‐20, Siemens Advia 2120i, Abbott Alinity Hq and Abbot Cell Dyn Sapphire hematology analyzers. The results were compared to control samples and the bias was determined.ResultsMost parameters, including all cell counts, hematocrit and MCV, showed a non‐significant bias compared to control. However, the standard, total hemoglobin (Hb) measurement as well as MCH and MCHC showed poor agreement with control, as HBOC‐201 was included in this measurement. Yet, the flow cytometry‐based Hb method quantified intracellular Hb in spiked samples, excluding HBOC‐201.ConclusionOf all included hematology parameters, only total Hb and the associated MCH and MCHC suffered from interference. In contrast, the flow cytometry‐based Hb measurement provided an accurate measure of intracellular Hb. The difference between total Hb and cellular Hb represents the HBOC‐201 concentration and can be used to monitor HBOC‐201 treatment.